Ask about this productRelated genes to: MUC6 antibody
- Gene:
- MUC6 NIH gene
- Name:
- mucin 6, oligomeric mucus/gel-forming
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 11p15.5
- Locus Type:
- gene with protein product
- Date approved:
- 1992-09-29
- Date modifiied:
- 2018-11-16
Related products to: MUC6 antibody
Related articles to: MUC6 antibody
- We aimed to synthesize current evidence on the clinicopathological features, diagnostic strategies, treatment modalities, and outcomes of gastric-type adenocarcinoma (GAS) of the cervix, a rare and aggressive HPV-independent subtype of cervical adenocarcinoma. - Source: PubMed
Publication date: 2026/03/07
Tjokroprawiro Brahmana AskandarSulistya Hanif ArdiansyahWijaya NicholasRahma Annisa AghniaNovitasari KhoirunnisaUlhaq Renata AlyaWaluyo Setyo TeguhWang Peng-Hui - We report a multicystic intrahepatic neoplasm in a 54-year-old Japanese woman, representing a previously unrecognized subtype. Grossly, the lesion was a well-demarcated multicystic tumor with focal papillary projections. Histologically, the cysts were lined by columnar to cuboidal neoplastic cells with brush border-like luminal microvilli, abundant granular eosinophilic cytoplasm, and small round nuclei. The cystic lumina contained colloid-like secretion, and bile-filled glands were occasionally observed. The septa were composed of thin hepatocellular parenchyma. Immunohistochemically, the tumor cells were positive for CD10, CK7, CK19, EpCAM, and SPINK1 and negative for HepPar1, MUC1, MUC2, MUC5AC, and MUC6. Whole-exome sequencing identified a pathogenic somatic KRAS p.G12V variant. RNA sequencing detected no PRKACA/B fusions. Single-cell spatial transcriptomics demonstrated that tumor cells clustered most closely with septal and medium-sized interlobular bile ducts. Gene set activity analysis showed significant suppression of gene sets downregulated by KRAS activation and upregulation of KRAS dependency signature gene sets in tumor cells. These findings distinguish this lesion from established entities of intrahepatic biliary cystic neoplasms, including intraductal papillary neoplasm, intraductal tubulopapillary neoplasm, intraductal oncocytic papillary neoplasm, and mucinous cystic neoplasm. We propose the designation "eosinophilic biliary cystic neoplasm of the liver" for this distinct intrahepatic biliary neoplasm. - Source: PubMed
Tanaka MarikoKoinuma DaizoHinata MunetoshiTakeshita KimikoYasunaga YoichiSakuma KeiTakamoto TakeshiNishioka YujiroHasegawa KiyoshiNakai YudaiUshiku Tetsuo - To investigate the histological and immunohistochemical characteristics of epithelial neoplasia of the extrahepatic bile ducts (EHBD) and to develop a diagnostic algorithm. - Source: PubMed
Suraev D EKalinin D VMarinova L APaklina O VKanner D Yu - Discovery on Gastrointestinal stromal tumour (DOG1) could deliver mitogen/survival signalling in colorectal carcinoma (CRC) cell lines. DOG1 is a major calcium-activated chloride channel expressed in mesenchymal and epithelial cells where it governs secretion of fluid and mucus. This study details DOG1 expression in various histopathological subtypes of CRC and assesses the relationship between DOG1 expression and an immunophenotype based on the secreted gel-forming mucins, as well as molecular groups of CRCs. A selection of 93 CRCs was analysed for clinicopathological data, RAS and BRAF mutations, microsatellite instability status, and mismatch-repair proteins (MLH1, MSH2, MSH6, PMS2). Their DOG1, MUC2, MUC5AC, MUC6, CDX2, keratin-20, and keratin-7 immunoprofiles were then compared with histopathology and molecular features of CRC. The prognostic relevance of DOG1 was assessed using univariate and multivariate survival analyses. DOG1 was detected in neoplastic cells and cancer-associated fibroblasts (CAFs) of 45 and 41 CRCs, respectively. In a clustering study, high expression of DOG1 in neoplastic cells was found in (i) various histological subtypes of adenocarcinomas with a gastric-like phenotype, BRAF mutation, and microsatellite instability high (MSI-H) and (ii) adenocarcinomas with a mucinous component, KRAS mutation, and microsatellite stability status (MSS). CAF DOG1 expression was identified in MSS conventional adenocarcinomas. DOG1 expression in tumour cells was associated with no benefit from adjuvant chemotherapy. DOG1-positive CAFs were associated with better overall survival. This study suggests that DOG1 expression is detected in a high proportion of CRC because it is expressed in neoplastic cells of various histological subtypes of CRC that secrete gel-forming mucins, independently of mucinous features or in CAFs of conventional adenocarcinomas. - Source: PubMed
Publication date: 2026/03/07
Baron JulieLagrue EricNormand AdelineDenis Marc GDuchalais EmilieMosnier Jean-François - Gastric signet ring cell carcinoma (GSRCC) is a special type of gastric cancer common in young women. Diffuse gastric cancer (DGC) begins with intramucosal lesions comprising differentiated GSRCC cells. Genetically, GSRCC and DGC are clonally identical, with their morphology influenced by extracellular Wnt signaling. Interestingly, Wnt activation facilitates the transition of indolent GSRCC cells into more invasive DGC cells, indicating the high plasticity of GSRCC cells. With respect to its cellular origin, GSRCC may originate from MUC5AC-/MUC6- pre-pit cells in the proliferative area of the gastric gland. Importantly, the tumor immune microenvironment (TIM) of GSRCC has unique characteristics. Compared with that of non-GSRCC, the TIM of GSRCC seems to be in a relatively "quiescent" state, and CD4 and CD8 T cells are difficult to activate. Moreover, compared with non-GSRCC patients, GSRCC patients have significantly greater Treg infiltration and significantly fewer CD8 T effector cells. This immune "quiescent" state may explain the poor response to immunotherapy in patients with GSRCC. Notably, the depletion of CXCL13 derived from exhausted CD8 T cells (CD8-Tex) and the absence of mature tertiary lymphoid structures are key reasons for the low response to immunotherapy in patients with GSRCC. Therefore, for patients with GSRCC, enhancing the ability of CD8-Tex cells to produce CXCL13 may be the key to improving the immune therapy response. In this review, we explore recent key findings on GSRCC, focusing on molecular mechanisms, immune regulation, and prospective research directions to improve clinical applications. - Source: PubMed
Publication date: 2026/03/27
Wang QianZhou ShuaiFang XiongchaoHe XianliWang GangWang Nan